Encap Drug Delivery, part of Capsugel’s Dosage Form Solutions (DFS) business, has entered a collaboration with Lipocine, Inc. to manufacture Phase III trial and ICH stability registration batches of Lipocine’s oral testosterone product, LPCN 1021.   The product will be manufactured at Encap’s high-potency R&D suite in Livingston, Scotland. Encap has completed the transfer of the manufacturing process and validation of all related test methods for LPCN 1021 to its Livingston...